

Adalimumab (Humira®)

Selected References:

- Akiyama S, et al. 2023. Pregnancy and medications for inflammatory bowel disease: An updated narrative review. *World Journal of Clinical Cases*, 11(8): 1730.
- Ben-Horin S, et al. 2010. Adalimumab level in breast milk of a nursing mother. *Clin Gastroenterol Hepatol*;8:475-6.
- Burmester GR, et al. 2017. Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. *Ann Rheum Dis*. 76(2):414-417.
- Bröms G, et al. 2016. Low risk of birth defects for infants whose mothers are treated with anti-tumor necrosis factor agents during pregnancy. *Clin Gastroenterol Hepatol* 14(2):234-241.
- Bröms G, et al. 2020. Anti-TNF treatment during pregnancy and birth outcomes: a population-based study from Denmark, Finland, and Sweden. *Pharmacoepidemiology and Drug Safety*. 29(3): 316-327.
- Beaulieu DB, et al. 2018. Use of biologic therapy by pregnant women with inflammatory bowel disease does not affect infant response to vaccines. *Clin Gastroenterol Hepatol*. 16: 99-105.
- Carter JD, et al. 2009. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. *The Journal of Rheumatology* 36:3.
- Carter JD, et al. 2006. Tumor necrosis factor-alpha inhibition and VATER association: a causal relationship. *J Rheumatol* 33(5):1014-1017.
- Chambers CD, et al. 2019. Birth outcomes in women who have taken adalimumab in pregnancy: A prospective cohort study. *PLoS One* 14 (10) e0223603.
- Chaparro M, et al. 2018. Long-Term Safety of In Utero Exposure to Anti-TNF α Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study. *Am J Gastroenterol*. 113: 396-403. Clark DA. 2010. Anti-TNF α therapy in immune-mediated subfertility: state of the art. *J Reprod Immunol*. 85(1):15-24.
- Cooley LF, et al. 202. Anti-TNF agents and potential effects on male fertility: are men being counseled?." *BMC urology*. 20: 1-6.
- Diav-Citrin O, et al. 2014. Pregnancy outcome following gestational exposure to TNF-alpha-inhibitors: A prospective, comparative, observational study. *Reprod Toxicol*; 43: 78-84.
- Flatman LK, et al. 2025 Serious Infections in Offspring Exposed to Tumour Necrosis Factor Inhibitors During Pregnancy: Comparison of Timing During Pregnancy and Placental Transfer Ability. *Arthritis Rheumatol*.
- Fritzsche J, et al. 2012. Infliximab and adalimumab use during breastfeeding. *J Clin Gastroenterol*; 46:718-719.
- Götestam Skorpen C, et al. 2016. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. *Ann Rheum Dis*. 75:795-810.
- Hart A, et al. 2022. Observational data from adalimumab post-marketing PYRAMID registry of patients with Crohn's disease who became pregnant: A post hoc analysis. *United European Gastroenterology Journal*. 10(5): 485-495.
- Hoxha A, et al. 2017. Pregnancy and foetal outcomes following anti-tumor necrosis factor alpha therapy: A prospective multicenter study. *Joint Bone Spine* 84(2):169-173.
- Huang W, et al. 2024. Anti-tumor necrosis factor- α therapy may not be safe during pregnancy in women with inflammatory bowel disease: an updated meta-analysis and systematic review. *BMC Pregnancy Childbirth*. 2024;24(1):251.
- Jeong YD, et al. 2025. Biologics Use for Psoriasis during Pregnancy and Its Related Adverse Outcomes in Pregnant Women and Newborns: Findings from WHO Pharmacovigilance Study. *Int Arch Allergy Immunol*. 186(6):579-593.
- Johansen CB, et al. 2018. The use and safety of TNF inhibitors during pregnancy in women with psoriasis: A review. *Int J Mol Sci*. 19(5):1349

- Julsgaard M, et al. 2013. Adalimumab levels in an infant. *J Crohns Colitis*;7(7):597-598.
- Kawai Y, et al. 2019. Pregnancy outcomes of patients exposed to adalimumab in Japan. *Dig Dis* 37(2): 123-130.
- Laube R, et al. 2023. Australian inflammatory bowel disease consensus statements for preconception, pregnancy and breast feeding. *Gut* 72(6): 1040-1053.
- Leung Y, et al. 2014. Management of the pregnant inflammatory bowel disease patient on anti-tumor necrosis factor: state of the art and future directions. *Can J Gastroenterol Hepatol*; 28(9):505-509.
- Liu Q, et al. 2025. Abortion adverse events associated with adalimumab, etanercept, ustekinumab, and dupilumab during pregnancy: A pharmacovigilance study based on FDA adverse event reporting system. *Drug Discov Ther.* 2025;19(3):160-173.
- Lund T, et al. 2016. Use of TNF-inhibitors and ustekinumab for psoriasis during pregnancy: A patient series. *Derm Therapy.* May; 30 (3)
- Luu M, et al. 2018. Continuous anti-TNF α use throughout pregnancy: possible complications for the mother but not for fetus. A retrospective cohort on the French National Health Insurance Database (EVASION). *ACG*, 113(11):1669-1677.
- Mahadevan U, et al. 2014. Achievement of developmental milestones among offspring of women with inflammatory bowel disease: the PIANO registry. *Gastroenterology* 146(5):1.
- Mahadevan U, et al. 2019. Inflammatory bowel disease in pregnancy clinical care pathway: A report from the American Gastroenterological Association IBD parenthood project working group. *Gastroenterology* 156:1508-1524.
- Matro R, et al. 2018. Exposure concentrations of infants breastfed by women receiving biologic therapies for inflammatory bowel diseases and effects of breastfeeding on infections and development. *Gastroenterology* 155:696-704.
- Micu MC, et al. 2014. TNF-alpha inhibitors do not impair sperm quality in males with ankylosing spondylitis after short-term or long-term treatment. *Rheumatology (Oxford)*. Jul;53(7):1250-1255.
- Mishkin DS, et al. 2006. Successful use of adalimumab (Humira) for Crohn's disease in pregnancy. *Inflamm Bowel Dis.* 12:827-828.
- Nielsen O, et al. 2022. Biologics for inflammatory bowel disease and their safety in pregnancy: a systematic review and meta-analysis. *Clinical Gastroenterology and Hepatology*. 20(1): 74-87.
- Palomino L, et al. 2025. Psychomotor Development in Infants Following Maternal Exposure to Biologics: Results From the DUMBO Registry. *Clin Gastroenterol Hepatol*. Online ahead of print.
- Picardo S, et al. 2019. A pharmacological approach to managing inflammatory bowel disease during conception, pregnancy and breastfeeding: Biologic and oral small molecule therapy. *Drugs* 79:1053-1063.
- Ramonda R, et al. 2014. Influence of tumor necrosis factor alpha inhibitors on testicular function and semen in spondyloarthritis patients. *Fertil Steril*; 101(2):359-365.
- Roux CH, et al. 2006. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)- α therapy. *Rheumatology* 46:695-698. Rüegg L, et al. 2025. EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update. *Ann Rheum Dis.* 2025;84(6):910-926.
- Russell MD, et al. 2023. British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: Immunomodulatory anti-rheumatic drugs and corticosteroids. *Rheumatology*. 62: e48-88.
- Sammaritano LR, et al. 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. *Arthritis Rheumatol.* 72:529-556.
- Schnitzler F et al. 2011. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. *Inflamm Bowel Dis.* 17(9):1846-1854.
- Shihab Z, et al. 2016. Anti-tumour necrosis factor α therapies and inflammatory bowel disease pregnancy outcomes: a meta-analysis. *Journal of Crohn's and Colitis*. 10(8): 979-988.
- Smith CH, et al. 2020. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: A rapid update. *Br J Dermatol.* 183:628-637.
- Truta B, et al. 2022. Outcomes of Continuation vs Discontinuation of Adalimumab Therapy During Third Trimester of Pregnancy in Inflammatory Bowel Disease. *Gastro Hep Advances.* 1(5):785-791.

- Villiger PM, et al. 2010. Effects of TNF antagonists on sperm characteristics in patients with spondyloarthritis. *Ann Rheum Dis* 69(10): 1842-1844.
- Viktil KK, et al. 2012. Outcomes after anti-rheumatic drug use before and during pregnancy: a cohort study among 150 000 pregnant women and expectant fathers. *Scandinavian Journal of Rheumatology*, 41(3): 196-201.
- Wang H, et al. 2022. Comparative safety of infliximab and adalimumab on pregnancy outcomes of women with inflammatory bowel diseases: a systematic review & meta-analysis. *BMC Pregnancy and Childbirth*. 22(1): 1-10.

问题？致电 866.626.6847 | 短信 855.999.3525 | 在 [MotherToBaby.org](https://www.MotherToBaby.org) 上发送电子邮件或聊天。

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 2025年12月1日。

Adalimumab (Humira®)

Selected References:

- Afrman JJ, et al. 2020. Therapeutic Drug Monitoring of Antiepileptic Drugs in Women with Epilepsy Before, During, and After Pregnancy. *Clin Pharmacokinet*, 59(4):427-445.
- Alsaad AMS, et al. 2015. First trimester exposure to topiramate and the risk of oral clefts in the offspring: A systematic review and meta-analysis. *Reprod Toxicol*, 53:45-50.
- Blotière PO, et al. 2020. Risk of early neurodevelopmental outcomes associated with prenatal exposure to the antiepileptic drugs most commonly used during pregnancy: a French nationwide population-based cohort study. *BMJ open*, 10(6):e034829.
- Blotière PO, et al. 2019. Risks of 23 specific malformations associated with prenatal exposure to 10 antiepileptic drugs. *Neurology*, 93(2):e167-80.
- Bjork MH, et al. 2022. Association of prenatal exposure to antiseizure medication with risk of autism and intellectual disability. *JAMA Neurol*, 79(7):672.
- Bozhinov PSB, et al. 2004. Normalisation of impaired reproduction functions after switching to topiramate monotherapy. *Epilepsia*, 45(Suppl 3):152.
- Bromley RL, et al. 2016. Cognition in school-age children exposed to levetiracetam, topiramate, or sodium

valproate. *Neurology*, 87(18):1943-53.

- Christensen J, et al. 2024. Prenatal exposure to antiseizure medications and fetal growth: a population-based cohort study from the Nordic countries. *Lancet, Reg Health Eur*, 38:100849.
- Committee on Drugs. 2001. The transfer of drugs and other chemicals into human milk. *Pediatrics*, 108(3):776-789.
- Dooze DR, et al. 2003. Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects. *Epilepsia*, 44(4):540-549.
- Fröscher W, et al. 2006. Topiramate use during breast feeding. *Aktuel Neurol*, 33:215-217.
- Gentile S. 2009. Topiramate in pregnancy and breastfeeding. *Clin Drug Investig*, 29:139-141.
- Hao N, et al. 2025. Seizure control and pregnancy outcomes in Chinese women with epilepsy: A prospective multicenter cohort study. *Epilepsia*, 66(5):1573-1584.
- Heinonen OP, Slone D, Shapiro S. 1977. Birth defects and drugs in pregnancy. Littleton, MA: John Wright-PSG, pp 389, 391-392, 394, 443, 478, 497.
- Hernandez-Diaz S, et al., for the North American AED Pregnancy Registry. 2012. Comparative safety of antiepileptic drugs during pregnancy. *Neurology*, 78:1692-1699.
- Hernandez-Diaz S, et al. 2014. Association between topiramate and zonisamide use during pregnancy and low birth weight. *Ob Gyn*, 123(1):21-28.
- Hernandez-Diaz S, et al. 2017. Fetal growth and premature delivery in pregnant women on antiepileptic drugs. *Ann Neurol*, 82(3):457-465.
- Hernandez-Diaz S, et al. 2018. Topiramate use early in pregnancy and the risk of oral clefts: a pregnancy cohort study. *Neurology*, 90(4):e342-351.
- Hernandez-Diaz S, et al. 2024. Risk of autism after prenatal topiramate, valproate, or lamotrigine exposure. *N Engl J Med*, 390:1069-1079.
- Hernandez-Diaz S, et al., 2025. Use of Antiseizure Medications Early in Pregnancy and the Risk of Major Malformations in the Newborn. *Neurology*, 105(3):e213786.
- Holtkamp M, et al. 2005. Erectile dysfunction with topiramate. *Epilepsia*, 46(1):166-167.
- Johannessen SI, et al. 2005. Levetiracetam concentrations in serum and in breast milk at birth and during lactation. *Epilepsia*, 46:775-777.
- Keni RR, et al. 2018. Teratogenicity of antiepileptic dual therapy: Dose-dependent, drug-specific, or both?. *Neurology*, 90(9): e790-796.
- Keni RR, et al. 2020. Anti-epileptic drug and folic acid usage during pregnancy, seizure and malformation outcomes: Changes over two decades in the Kerala Registry of Epilepsy and Pregnancy. *Epilepsy Research*, 159:106250.
- Laspro M, et al. 2025. Association of Commonly Prescribed Antepartum Medications and Incidence of Orofacial Clefting. *The Cleft Palate Craniofacial Journal*, 62(7):1164-1174.
- Madley-Dowd P, et al. 2024. Antiseizure medication use during pregnancy and children's neurodevelopmental outcomes. *Nature Communications*, 15(1).
- Öhman I, et al. 2002. Topiramate kinetics during delivery, lactation, and in the neonate: Preliminary observations. *Epilepsia*, 43:1157-1160.
- Öhman I, et al. 2007. Topiramate kinetics during lactation. *Epilepsia*, 48(Supp 7):156-157.
- Ornoy A, et al. 2017. Antidepressants, antipsychotics, and mood stabilizers in pregnancy: what do we know and how should we treat pregnant women with depression. *Birth defects research*, 109(12):933-956.
- Tomson T, et al. 2018. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. *The Lancet Neurology*, 17(6):530-538.
- Vajda FJ, et al. 2016. Antiepileptic drug combinations not involving valproate and the risk of fetal malformations. *Epilepsia*, 57(7):1048-1052.
- Vajda FJ, et al. 2018. Antiepileptic drug polytherapy in pregnant women with epilepsy. *Acta Neurologica Scandinavica*, 138(2):115-121.

- Vajda FJ, et al. 2019. Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register. *Seizure*, 65:6-11.
- Vajda FJ, et al. 2020. Preexisting illness, fetal malformation, and seizure control rates in pregnant women with epilepsy. *Epilepsy & Behavior*; 9:106481.
- Veroniki AA, et al. 2017. Comparative safety of anti-epileptic drugs during pregnancy: a systematic review and network meta-analysis of congenital malformations and prenatal outcomes. *BMC medicine*. 15(1):95.
- Westergren T, et al. 2014. Probable topiramate-induced diarrhea in a 2-month-old breast-fed child – A case report. *Epilepsy Behav Case Rep*, 2:22-23. Weston J, et al. 2016. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. *Cochrane Database Syst Rev*, 11: Cd010224.
- Wu M, et al. 2016. Spermatorrhea and loss of libido induced by topiramate: First case report and review of literature. *Clin Neuropharm*, 39:325-326.
- Zeng Y, et al. 2025. Safety concerns of maternal antiseizure medications exposure on perinatal and offspring outcomes: a disproportionality analysis based on FDA adverse event reporting system. *Journal of Neurology*, 272:429.

问题？致电 866.626.6847 | 短信 855.999.3525 | 在 [MotherToBaby.org](https://www.MotherToBaby.org) 上发送电子邮件或聊天。

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 2025年12月1日。

Adalimumab (Humira®)

Selected References:

- Amundsen S, et al. 2015. Pharmacological treatment of migraine during pregnancy and breastfeeding; *Nat. Reviews Neurol*. 11(4): 209-215.
- Bandoli G, et al. 2020. Migraines During Pregnancy and the Risk of Maternal Stroke. *JAMA Neurol*. 77(9):1177-79.
- Bánhidý F, et al. 2006. Maternal severe migraine and risk of congenital limb deficiencies. *Birth Defects Res a Clin Mol Teratol*. 76(8):592-601.

- Conijn M, et al. 2024. Breastfeeding-related adverse drug reactions of triptans: A descriptive analysis using four pharmacovigilance databases. *Breastfeed Med.* 19:645-51.
- Cunningham M, et al. 2009. The safety of sumatriptan and naratriptan in pregnancy: what have we learned? *Headache.* 49(10):1414-22.
- David PS, et al. 2014. Migraine in pregnancy and lactation. *Curr Neurol Neurosci Rep.* 14(4):439.
- Duong S, et al. 2010. Safety of triptans for migraine headaches during pregnancy and breastfeeding. *Can Fam Physician.* 56(6):537-9.
- Ephross AS, et al. 2014. Final results from the 16-year sumatriptan, naratriptan, and treximet pregnancy registry. *Headache.* 54(3):1158-1172.
- Harris GE, et al. 2018. Prenatal triptan exposure and neurodevelopmental outcomes in 5-year-old children: Follow-up from the Norwegian Mother and Child Cohort Study. *Paediatr Perinat Epidemiol.* 32(3):247-255.
- Jarvis S, et al. 2018. Managing migraine in pregnancy. *BMJ* 360:k80.
- Källén B, et al. 2011. Delivery outcome after maternal use of drugs for migraine: a register study in Sweden. *Drug Saf.* 34(8):691-703.
- MacGregor AE, et al. 2014. Migraine in pregnancy and lactation. *Neurol Sci.* 35(Suppl 1): S61-S64.
- Marchenko A, et al. 2015. Pregnancy outcome following prenatal exposure to triptan medications: a meta-analysis. *Headache.* 55(10):1478.
- Miller C & Vollbracht S. 2021. Neurology of Preeclampsia and Related Disorders: An Update in Neuro-obstetrics. *Curr Pain Headache Rep.* 25(6):40.
- Negro A, et al. 2017. Headache and pregnancy: a systematic review. *The Journal of Headache and Pain* 18(1):106.
- Nezvalová-Henriksen K, et al. 2010. Triptan exposure during pregnancy and the risk of major congenital malformations and adverse pregnancy outcomes: results from the Norwegian Mother and Child Cohort Study. *Headache.* 50(4):563-75.
- Nezvalová-Henriksen K, et al. 2013. Triptan safety during pregnancy: a Norwegian population registry study. *Eur J Epidemiol.* 28(9):759-69.
- Olesen C, et al. 2000. Pregnancy outcome following prescription for sumatriptan. *Headache.* 40(1):20-4.
- Spielmann K, et al. 2018. Pregnancy outcome after anti-migraine triptan use: a prospective observational cohort. *Cephalalgia.* 38(6):1081-1092.
- Wabnitz A, Bushnell C. 2015. Migraine, cardiovascular disease, and stroke during pregnancy: systematic review of the literature. *Cephalalgia.* 35(2):132-9.
- Wojnar-Horton RE, et al. 1996. Distribution and excretion of sumatriptan in human milk. *Br J Clin Pharmacol.* 41(3):217-21.
- Wood ME, et al. 2016. Prenatal Triptan Exposure and Internalising and Externalising Behaviour Problems in 3-Year-Old Children: Results from the Norwegian Mother and Child Cohort Study. *Paediatr Perinat Epidemiol.* 30(2):190-200.

问题？致电 866.626.6847 | 短信 855.999.3525 | 在 [MotherToBaby.org](https://www.MotherToBaby.org) 上发送电子邮件或聊天。

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 2025年12月1日。

Adalimumab (Humira®)

Selected References:

- American College of Obstetricians and Gynecologists (ACOG). 2018. Moderate caffeine consumption during pregnancy. <https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Obstetric-Practice/Moderate-Caffeine-Consumption-During-Pregnancy?IsMobileSet=false>.
- American Society for Reproductive Medicine (ASRM). 2022. Optimizing natural fertility: A Committee Opinion. <https://www.asrm.org/practice-guidance/practice-committee-documents/optimizing-natural-fertility-a-committee-opinion-2021/>
- Bech BH, et al. 2005. Coffee and fetal death: a cohort study with prospective data. *Am J Epidemiol*, 162(10):983-990.
- Brown ML, et al. 2006. Maternal exposure to caffeine and risk of congenital anomalies: a systematic review. *Epidemiology*, 17(3):324-331.
- CaffeineInformer. 2019. Caffeine in Guarana. <https://www.caffeineinformer.com/caffeine-content/guarana>. Accessed October 22, 2019.
- Chiaffarino F, et al. 2006 Coffee drinking and risk of preterm birth. *Eur J Clin Nutr*; 60:610-613.
- Christian M and Brent R. 2001. Teratogen update: Evaluation of the reproductive and developmental risks of caffeine. *Teratology*, 64:51-78.
- Cnattingius S, et al. 2000. Caffeine intake and the risk of first-trimester spontaneous abortion. *N Engl J Med*, 343:1839-1845.
- Committee on Drugs, 2001. American Academy of Pediatrics. The transfer of drugs and other chemicals in human milk. *Pediatrics*, 108(3):776-789.
- D'Urso S, et al. 2024. Mendelian randomization analysis of maternal coffee consumption during pregnancy on offspring neurodevelopmental difficulties in the Norwegian Mother, Father and Child Cohort Study (MoBa). *Psychological medicine*, 54(12):1-14.
- Eskenazi B. 1999. Caffeine—Filtering the facts. *N Engl J Med*, 341:1688-1689. Hatch E and Bracken M. 1993. Association of delayed conception with caffeine consumption. *Am J Epidemiol*, 138:1082-1091. Klebanoff M, et al. 1999. Maternal serum paraxanthine, a caffeine metabolite, and the risk of spontaneous abortion. *New Engl J Med*, 341:1639-1644.
- Klebanoff M and Keim SA. 2015. Maternal caffeine intake during pregnancy and child cognition and behavior at 4 and 7 years of age. *Am J Epidemiol*, 182(12):1023-1032.
- Kobayashi S, et al. 2019. Dose-dependent associations between prenatal caffeine consumption and small for gestational age, preterm birth, and reduced birthweight in the Japan Environment and Children's Study. *Paediatr Perinat Epidemiol*, 33:185-194.
- Kukkonen A, et al. 2024. Maternal caffeine intake during pregnancy and the risk of delivering a small for gestational age baby: Kuopio Birth Cohort. *Archives of gynecology and obstetrics*, 310(1):359-368.
- Larroque B, et al. 1993. Effects on birthweight of alcohol and caffeine consumption during pregnancy. *Am J*

Epidemiol, 137:941-950.

- Lyngsø J, et al. 2017. Association between coffee or caffeine consumption and fecundity and fertility: a systematic review and dose-response meta-analysis. Clin Epidemiol, 9:699-719.
- Maslova E, et al. 2010. Caffeine consumption during pregnancy and risk of preterm birth: a meta-analysis. Am J Clin Nutr, 92:1120-1132.
- Matijasevich A, et al. 2006. Maternal caffeine consumption and fetal death: a case-control study if Uruguay. Paediatr Perinat Epidemiol, 20(2):100-109.
- Mills JL, et al. 1993. Moderate caffeine use and the risk of spontaneous abortion and intrauterine growth. JAMA, 269:593-597.
- Okubo H, et al. 2015. Maternal total caffeine intake, mainly from Japanese and Chinese tea, during pregnancy was associated with risk of preterm birth: the Osaka Maternal and Child Health Study. Nutr Res, 35:309-316.
- Ricci E, et al. 2017. Coffee and caffeine intake and male infertility: a systematic review. Nutr J, 16(1):37.
- Saimaiti A, et al. 2023. Dietary sources, health benefits, and risks of caffeine. Crit Rev Food Sci Nutr, 63(29):9648-9666.
- Ruderman RS, et al. 2025. Periconceptual Caffeine Intake and Adverse Pregnancy Outcomes: Results From the nuMoM2b Cohort. BJOG: an international journal of obstetrics and gynaecology, 10.1111/1471-0528.70018.
- Savitz DA, et al. 2008. Caffeine and miscarriage risk. Epidemiology, 19(1):55-62. Schellhas L, et al. 2023. Maternal caffeine consumption during pregnancy and offspring cord blood DNA methylation: an epigenome-wide association study meta-analysis. Epigenomics, 15(22):1179-1193.
- Shu XO, et al. 1995. Maternal smoking, alcohol drinking, caffeine consumption and fetal growth: Results from a prospective study. Epidemiology, 6:115-120.
- Weng, X, et al. 2008. Maternal caffeine consumption during pregnancy and the risk of miscarriage: a prospective cohort study. Am J Obstet Gynecol, 279:e1-e8.
- Zhang H, et al. 2024. Association between tea, coffee and caffeine consumption and risk of female infertility: a cross-sectional study. Reproductive biology and endocrinology: RB&E, 22(1):91.

问题？致电 866.626.6847 | 短信 855.999.3525 | 在 [MotherToBaby.org](https://www.MotherToBaby.org) 上发送电子邮件或聊天。 .

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 2025年12月1日.

Adalimumab (Humira®)

Selected References:

- ANI Pharmaceuticals. 2024. Etodolac product labeling. Available at: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=420c7b62-3bea-4d6b-82e0-ab1c176c7f1e>. Accessed 21 July 2025.
- Choi E-Y, et al. 2023. Neonatal and maternal adverse outcomes and exposure to nonsteroidal anti-inflammatory drugs during early pregnancy in South Korea: a nationwide cohort study. *PLoS Med*, 20(2):e1004183.
- Dawood MY. 1993. Nonsteroidal antiinflammatory drugs and reproduction. *Am J Obstet Gynecol*, 169(5):1255-1265.
- Daniel S, et al. 2012. Major Malformations Following Exposure to Nonsteroidal Antiinflammatory Drugs During the First Trimester of Pregnancy. *J Rheumatol* 39(11) 2163-2169.
- Daniel S, et al. 2014. Fetal exposure to nonsteroidal anti-inflammatory drugs and spontaneous abortion. *Can Med Assoc J* 186(5):E177-E182.
- Daniel S, et al. 2015. NSAIDs and spontaneous abortions – true effect or an indication bias? *Br J Clin Pharmacol*, 80(4):750-754.
- Dathe K, et al. 2018. No evidence of adverse pregnancy outcome after exposure to ibuprofen in the first trimester—Evaluation of the national Embryotox cohort. *Reproductive Toxicology*, 79: 32-38.
- Ericson A and Kallen BA. 2001. Nonsteroidal anti-inflammatory drugs in early pregnancy. *Reprod Toxicol*, 15:371-
- Janssen NM and Genta MS. 2000. The effects of immunosuppressive and anti-inflammatory medication on fertility, pregnancy, and lactation. *Arch Intern Med*, 160:610-619.
- Nezvalova-Henriksen K et al. 2013. Effects of ibuprofen, diclofenac, naproxen, and piroxicam on the course of pregnancy and pregnancy outcome: a prospective study. *BJOG*, 120(8):948-959.
- Nielsen GL, et al. 2001. Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs: population based observational study and case-control study. *BMJ*, 322(7281):266-270.
- Nielsen GL, et al. 2004. Danish group reanalyses miscarriage in NSAID users. *BMJ*, 328(7431):109.
- U.S. Food and Drug Administration. 2020. FDA recommends avoiding use of NSAIDs in pregnancy at 20 weeks or later because they can result in low amniotic fluid. Available at: <https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-avoiding-use-nsaids-pregnancy-20-weeks-or-later-because-they-can-result-low-amniotic>. Accessed 21 July 2025.

问题？致电 866.626.6847 | 短信 855.999.3525 | 在 [MotherToBaby.org](https://www.MotherToBaby.org) 上发送电子邮件或聊天。

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 2025年12月1日.